arsenic trioxide has been researched along with abt-199 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Naoe, T | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Li, Y; Xu, Q; Yu, J; Zhang, K | 1 |
| Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH | 1 |
| Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B | 1 |
2 review(s) available for arsenic trioxide and abt-199
| Article | Year |
|---|---|
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
3 other study(ies) available for arsenic trioxide and abt-199
| Article | Year |
|---|---|
Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Ecchymosis; Female; Humans; Leukemia, Promyelocytic, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tretinoin | 2021 |
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin | 2022 |
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides | 2022 |